Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Jane M. Grant-Kels MD, FAAD Advisory Board

Eliot N. Mostow MD, MPH Associate Editor

Christen Maria Mowad MD Advisory Board

See All Experts

featured

Published in Dermatology

Journal Scan / Research · January 30, 2024

Safety and Efficacy of Treatment With Deucravacitinib in Patients With Scalp Psoriasis

Journal of the American Academy of Dermatology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Leon Kircik MD

Journal of the American Academy of Dermatology

Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis

J Am Acad Dermatol 2023 Dec 18;[EPub Ahead of Print], A Blauvelt, P Rich, H Sofen, B Strober, JF Merola, M Lebwohl, A Morita, JC Szepietowski, J Lambert, L Hippeli, E Colston, E Balagula, S Banerjee, D Thaçi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Safety and Efficacy of Treatment With Deucravacitinib in Patients With Scalp Psoriasis

Additional Info

Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis

Further Reading

Association of Gabapentinoid Use With Risk of Hip Fracture

Outcomes of Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata With or Without Early Target Responses

Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Initially Treated With Baricitinib 4 mg

Clinical Safety and Efficacy of Dual-Wavelength Low-Level Light Therapy Among Patients With Androgenetic Alopecia

Efficacy of Treatment With Bimekizumab in Patients With Hidradenitis Suppurativa

Efficacy and Safety of Treatment With Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis

Relative Effect of a 0.8-mm Breslow Thickness on the Risk of Death Owing to Melanoma and Other Causes Among Patients With Thin Cutaneous Melanomas

Effectiveness of a Novel Treatment Regimen for Patients With Acne Vulgaris

Efficacy of a Novel Four-Step Skin Care Regimen in Improving Uneven Skin Tone

Outcomes of Treatment With CO2 Laser vs Surgical Deroofing in Patients With Hidradenitis Suppurativa Tunnels

Effectiveness of Treatment With Deucravacitinib in Patients With Plaque, Generalized Pustular, or Erythrodermic Psoriasis

Recently Updated